Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2010, Vol. 21 ›› Issue (3): 165-170 doi: 10.13538/j.1001-8042/nst.21.165-170

• LOW ENERGY ACCELERATOR AND RADIATION APPLICATIONS • Previous Articles     Next Articles

Development of 153Sm-bleomycin as a possible therapeutic complex

BAHRAMI-SAMANI Ali1 GHANNADI-MARAGHEH Mohammad2 JALILIAN Amir Reza2,* YOUSEFNIA Hassan2 MORADKHANI Sedigheh2 BOLOURINOVIN Fatemeh2   

  1. 1 Faculty of Nuclear Engineering and Physics, Amir Kabir University, Tehran, Iran 2 Radiopharmaceutical Research and Development Laboratories, Nuclear Science and Technology Research Institute, Tehran, Iran
BAHRAMI-SAMANI Ali, GHANNADI-MARAGHEH Mohammad. Development of 153Sm-bleomycin as a possible therapeutic complex.Nuclear Science and Techniques, 2010, 21(3): 165-170     doi: 10.13538/j.1001-8042/nst.21.165-170

Abstract:

Due to interesting therapeutic properties of 153Sm and antineoplastic antibiotic, bleomycin (BLM), 153Sm-bleomycin (153Sm-BLM) was developed as a possible therapeutic compound using 153SmCl3 and BLM. The 153SmCl3 was obtained by thermal neutron flux (5×1013 n·cm–2·s–1) of an enriched 152Sm2O3 sample, dissolved in acidic media. Under optimized conditions (room temperature, 45 min, 0.1 mg bleomycin for 740–3700 MBq 153SmCl3) a radiochemical purity over 98 % was obtained shown by HPLC (Specific activity = 55 TBq/mM). The 153SmCl3 and 153Sm-BLM were administered into wild-type rats up to 96 h followed by biodistribution. The SPECT imaging of labeled compound in wild-type rats was performed and significant image pattern was observed for a radiolabeled bleomycin compound. The 153Sm-BLM is a potential therapeutic compound and our experiments on this compound have shown satisfactory quality, and stability suitable for future therapeutic studies.

Key words: Bleomycin, Sm-153, Biodistribution, Radiolabeling